Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia

Pharmacopsychiatry

Volumn 44, Issue 4, 2011, Pages 135-141

  Xiang, Y T ^a,b,c   Wang, C Y ^a   Ungvari, G S ^d   Kreyenbuhl, J A ^b   Chiu, H F K ^c   Lai, K Y C ^c   Lee, E H M ^c   Bo, Q J ^a   Dixon, L B ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; UNDERWEIGHT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CHINA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OVERWEIGHT; PATIENT DROPOUTS; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; THINNESS; TIME FACTORS; YOUNG ADULT;

EID: 79959449683     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1277178     Document Type: Article

References (42)

1. Herva A, Laitinen J, Miettunen J et al,. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes 2006 30 520-527
2. McEvoy JP, Meyer JM, Goff DC et al,. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005 80 19-32 (Pubitemid 41587460)
3. Mukherjee S, Decina P, Bocola V et al,. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996 37 68-73 (Pubitemid 26024880)
4. Robinson DG, Woerner MG, Delman HM et al,. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 2005 31 705-722 (Pubitemid 41253320)
5. Weiss F. Group psychotherapy with obese disordered-eating adults with body-image disturbances: an integrated model. Am J Psychother 2004 58 281-303 (Pubitemid 41110614)
6. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002 63 1121-1128 (Pubitemid 36084056)
7. Wirshing DA, Wirshing WC, Kysar L et al,. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999 60 358-363 (Pubitemid 29289721)
8. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003 54 565-567 (Pubitemid 36752990)
9. Bobes J, Rejas J, Garcia-Garcia M et al,. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003 62 77-88 (Pubitemid 36588706)
10. Basile VS, Masellis M, McIntyre RS et al,. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001 62 45-66 (Pubitemid 32952694)
11. Park YM, Chung YC, Lee SH et al,. Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006 141B 394-397
12. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008 42 369-381 (Pubitemid 351877210)
13. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic-induced weight gain mechanisms and genetics. J Psychopharmacol 2006 20 15-18 (Pubitemid 44576653)
14. Yang LH, Chen TM, Yu ST et al,. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007 56 202-208
15. Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005 65 1113-1138 (Pubitemid 40840008)
16. Allison DB, Mentore JL, Heo M et al,. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 156 1686-1696 (Pubitemid 29517559)
17. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001 24 59-73 (Pubitemid 32113367)
18. Bai YM, Chen JY, Chen TT et al,. Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophr Res 2009 108 122-126
19. Lipkovich I, Jacobson JG, Hardy TA et al,. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 2008 8 78
20. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001 62 5-12 (Pubitemid 32952689)
21. Lee E, Leung CM, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychiatry 2004 65 864-866
22. de Leon J, Diaz FJ, Josiassen RC et al,. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol 2007 27 22-27 (Pubitemid 46105759)
23. Haas M, Eerdekens M, Kushner S et al,. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009 194 158-164
24. Wang CY, Xiang YT, Cai ZJ et al,. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 2010 167 676-685
25. Zhang MY. Chinese Version of Brief Psychiatric Rating Scale (in Chinese), in Handbook of Scales for Behavioral Medicine. Edited by Zhang ZJ. Jining, Chinese Journal of Behavioral Medical Science press 2001 140-142
26. Chinese Medical Association. Guideline for the Prevention and Treatment of Schizophrenia in China. Beijing, Chinese Medical Association 2003
27. Kinon BJ, Kaiser CJ, Ahmed S et al,. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005 25 255-258 (Pubitemid 40685790)
28. Tollefson GD, Beasley CM Jr, Tran PV et al,. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997 154 457-465 (Pubitemid 27147597)
29. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002 346 16-22 (Pubitemid 34438915)
30. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 1984 39 187-193 (Pubitemid 14156164)
31. Shen YC. Schizophrenia, in Psychiatry. Edited by Shen YC. Beijing, Peopleâs medical publishing house 2001 393-416
32. Henderson DC, Cagliero E, Gray C et al,. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000 157 975-981 (Pubitemid 30412350)
33. Parsons B, Allison DB, Loebel A et al,. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009 110 103-110
34. Basson BR, Kinon BJ, Taylor CC et al,. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001 62 231-238 (Pubitemid 32428761)
35. Purdon SE, Jones BD, Stip E et al,. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000 57 249-258 (Pubitemid 30140434)
36. Tran PV, Hamilton SH, Kuntz AJ et al,. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 17 407-418 (Pubitemid 27414397)
37. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004 24 429-436 (Pubitemid 38944142)
38. Kennedy JS, Bymaster FP, Schuh L et al,. A current review of olanzapineâs safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001 16 S33-S61 (Pubitemid 33741567)
39. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006 29 303-319
40. Lane HY, Chang YC, Cheng YC et al,. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry 2003 64 316-320
41. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003 59 19-27 (Pubitemid 35291087)
42. Williams R. Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001 62 282-289 (Pubitemid 32428768)